Overview

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Status:
Active, not recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.